Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Abroad (travel likely)RecruitingPHASE1
Conditions
Primary Myelofibrosis · Post-polycythemia Vera Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis · Chronic Myelomonocytic Leukemia · Polycythemia Vera · Essential Thrombocytosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Abigail Protocol Development Coordinator) · abigail.okeefe@fccc.edu · 215-728-2451
Study leads
Peter Abdelmessieh, DO, MSc
Principal Investigator
Fox Chase Cancer Center